HT
TVRD

Headlands Technologies’s Tvardi Therapeutics TVRD Stock Holding History

Headlands Technologies’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,431
Closed -$80K – 1358
2025
Q2 		$80K Buy
+3,431
New +$81.1K 0.01% 676
2023
Q4 		– Sell
-54
Closed -$3.25K – 1366
2023
Q3 		$3.25K Buy
+54
New +$5.07K ﹤0.01% 796

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Headlands Technologies's TVRD Position: Q3 2025 in Review

Headlands Technologies sold out of Tvardi Therapeutics (TVRD) in Q3 2025, closing a stake of 3,431 shares — an estimated $80K sold.

Headlands Technologies first reported a position in TVRD in Q3 2023 and held it in 2 quarters. The position peaked at $80K in Q2 2025. 73 funds tracked by Wall St. Rank hold TVRD as of Q3 2025.

  • Headlands Technologies reported no remaining Tvardi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Headlands Technologies sold 3,431 Tvardi Therapeutics shares in Q3 2025, an estimated $80K.
  • Headlands Technologies first reported a position in Tvardi Therapeutics in Q3 2023 and held it in 2 quarters.
  • Headlands Technologies's Tvardi Therapeutics position peaked at $80K in Q2 2025.
  • 73 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2025.

Based on Headlands Technologies's 13F filing for Q3 2025, filed 12 Nov 2025.